close
Add to watchlist
POZEN Inc (POZN) Healthcare, Biotechnology & Drugs
POZEN, Inc. engages in the development of pharmaceutical products for the treatment of acute and chronic pain, and other pain-related conditions. The company has development and commercialization alliances with GlaxoSmithKline for Treximet, which is used for the acute treatment of migraine attacks with or without aura in adults; and AstraZeneca for proprietary fixed dose combinations of naproxen with the proton pump inhibitor esomeprazole magnesium in a single tablet for conditions, such as osteoarthritis and rheumatoid arthritis in patients who are at risk for developing non-steroidal anti-inflammatory drug-associated gastric ulcers. POZEN, Inc. was founded in 1996 and is headquartered in Chapel Hill, North Carolina.
(login to add this stock to your watchlist or favorites)
Key Statistics
| Closing Price | 4.76 |
| Volume | 65211 |
| Volume Avg | 93018 |
| 52 Week High | 6.39 |
| 52 Week Low | 2.15 |
| PE | 3.44 |
| PE (group average) | 39 |
| EPS Year | 1.40 |
| EPS change Q/Q | 1000% |
| EPS change Q/Q Yr ago | -90% |
| EPS change Q/Q next Q est | -17.39% |
| EPS change Y/Y | 1000% |
| REV change Q/Q | -84.48% |
| REV change Q/Q Yr ago | -34.78% |
| EPS next Q est | -0.23 |
| EPS next Y est | -0.74 |
| Divident Annual | 0.00 |
| Dividend Yield | 0% |